Sebastian Scioli-Montoto

Dr. Sebastian Scioli-Montoto

Laboratorio de Investigación y Desarrollo de Bioactivos (LIDeB), Facultad de Ciencias Exactas, Universidad Naiconal de La Plata, La Plata, Buenos Aires, Argentina
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2020 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
SSSebastian Scioli-Montoto
Sebastian Scioli-Montoto
GMGiuliana Muraca
Giuliana Muraca
MRMaría Esperanza Ruiz
María Esperanza Ruiz
In the golden age of pharmaceutical nanocarriers, we are witnessing a maturation stage of the original concepts and ideas. There is no doubt that nanoformulations are extremely valuable tools for drug delivery applications; the current challenge is how to optimize them to ensure that they are safe, effective and scalable, so that they can be manufactured at an industrial level and advance to clinical use. In this context, lipid nanoparticles have gained ground, since they are generally regarded as non-toxic, biocompatible and easy-to-produce formulations. Pharmaceutical applications of lipid nanocarriers are a burgeoning field for the transport and delivery of a diversity of therapeutic agents, from biotechnological products to small drug molecules. This review starts with a brief overview of the characteristics of solid lipid nanoparticles and discusses the relevancy of performing systematic preformulation studies. The main applications, as well as the advantages that this type of nanovehicles offers in certain therapeutic scenarios are discussed. Next, pharmacokinetic aspects are described, such as routes of administration, absorption after oral administration, distribution in the organism (including brain penetration) and elimination processes. Safety and toxicity issues are also addressed. Our work presents an original point of view, addressing the biopharmaceutical aspects of these nanovehicles by means of descriptive statistics of the state-of-the-art of solid lipid nanoparticles research. All the presented results, trends, graphs and discussions are based in a systematic (and reproducible) bibliographic search that considered only original papers in the subject, covering a 7 years range (2013-today), a period that accounts for more than 60% of the total number of publications in the topic in the main bibliographic databases and search engines. Focus was placed on the therapeutic fields of application, absorption and distribution processes and current efforts for the translation into the clinical practice of lipid-based nanoparticles. For this, the currently active clinical trials on lipid nanoparticles were reviewed, with a brief discussion on what achievements or milestones are still to be reached, as a way of understanding the reasons for the scarce number of solid lipid nanoparticles undergoing clinical trials.

1 July 2018 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
SSSebastian Scioli-Montoto
Sebastian Scioli-Montoto
MSMaría Sbaraglini
María Sbaraglini
ATAlan Talevi
Alan Talevi
MCM. Couyoupetrou
M. Couyoupetrou
MIM. Di Ianni
M. Di Ianni
German A. IslanGerman A. Islan
German A. Islan

1 October 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Boris Rodenak-KladniewBoris Rodenak-Kladniew
Boris Rodenak-Kladniew
SSSebastian Scioli-Montoto
Sebastian Scioli-Montoto
MSMaría Sbaraglini
María Sbaraglini
MIM. Di Ianni
M. Di Ianni
MRMaría Esperanza Ruiz
María Esperanza Ruiz
German A. IslanGerman A. Islan
German A. Islan

9 January 2017 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
JMJuan F. Morales
Juan F. Morales
SSSebastian Scioli-Montoto
Sebastian Scioli-Montoto
PFPietro Fagiolino
Pietro Fagiolino
MRMaría Esperanza Ruiz
María Esperanza Ruiz
The Blood-Brain Barrier (BBB) is a physical and biochemical barrier that restricts the entry of certain drugs to the Central Nervous System (CNS), while allowing the passage of others. The ability to predict the permeability of a given molecule through the BBB is a key aspect in CNS drug discovery and development, since neurotherapeutic agents with molecular targets in the CNS should be able to cross the BBB, whereas peripherally acting agents should not, to minimize the risk of CNS adverse effects. In this review we examine and discuss QSAR approaches and current availability of experimental data for the construction of BBB permeability predictive models, focusing on the modeling of the biorelevant parameter unbound partitioning coefficient (Kp,uu). Emphasis is made on two possible strategies to overcome the current limitations of in silico models: considering the prediction of brain penetration as a multifactorial problem, and increasing experimental datasets through accurate and standardized experimental techniques.

17 August 2022 in Frontiers in Chemistry
Verified
Journal Article
Open access
SSSebastian Scioli-Montoto
Sebastian Scioli-Montoto
MSMaria Laura Sbaraglini
Maria Laura Sbaraglini
JCJose Sebastian Cisneros
Jose Sebastian Cisneros
CCCecilia Yamil Chain
Cecilia Yamil Chain
VFValeria Ferretti
Valeria Ferretti
MRMaría Esperanza Ruiz
María Esperanza Ruiz
Pharmacological treatments of central nervous system diseases are always challenging due to the restrictions imposed by the blood–brain barrier: while some drugs can effectively cross it, many others, some antiepileptic drugs among them, display permeability issues to reach the site of action and exert their pharmacological effects. The development of last-generation therapeutic nanosystems capable of enhancing drug biodistribution has gained ground in the past few years. Lipid-based nanoparticles are promising systems aimed to improve or facilitate the passage of drugs through biological barriers, which have demonstrated their effectiveness in various therapeutic fields, without signs of associated toxicity. In the present work, nanostructured lipid carriers (NLCs) containing the antiepileptic drug phenobarbital were designed and optimized by a quality by design approach (QbD). The optimized formulation was characterized by its entrapment efficiency, particle size, polydispersity index, and Z potential. Thermal properties were analyzed by DSC and TGA, and morphology and crystal properties were analyzed by AFM, TEM, and XRD. Drug localization and possible interactions between the drug and the formulation components were evaluated using FTIR. In vitro release kinetic, cytotoxicity on non-tumoral mouse fibroblasts L929, and in vivo anticonvulsant activity in an animal model of acute seizures were studied as well. The optimized formulation resulted in spherical particles with a mean size of ca. 178 nm and 98.2% of entrapment efficiency, physically stable for more than a month. Results obtained from the physicochemical and in vitro release characterization suggested that the drug was incorporated into the lipid matrix losing its crystalline structure after the synthesis process and was then released following a slower kinetic in comparison with the conventional immediate-release formulation. The NLC was non-toxic against the selected cell line and capable of delivering the drug to the site of action in an adequate amount and time for therapeutic effects, with no appreciable neurotoxicity. Therefore, the developed system represents a promising alternative for the treatment of one of the most prevalent neurological diseases, epilepsy.

5 July 2019 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
Maximiliano Luis CacicedoMaximiliano Luis Cacicedo
Maximiliano Luis Cacicedo
MRM. C. Ruiz
M. C. Ruiz
SSSebastian Scioli-Montoto
Sebastian Scioli-Montoto
MRMaría Esperanza Ruiz
María Esperanza Ruiz
MFM. A. Fernández
M. A. Fernández
Ignacio E. LeónIgnacio E. León
Ignacio E. León
Cancer is one of the main causes of mortality worldwide. Common therapy schemes are always based on chemotherapy, radiotherapy and/or surgery. Among chemotherapeutics, vanadium compounds have recently emerged as non-platinum antitumor agents. In this sense, Metvan ([VIVO(Me2phen)2(SO4)]) was identified as one of the most promising vanadium anticancer complexes. In this work, the Metvan compound was encapsulated into well designed and developed nanostructured lipid carriers (NLCs) with the aim of improving its biopharmaceutical profile with regards to bioavailability, degradation, solubility and cell up-take. A quality by design approach was followed to find the optimal nanoparticle formulation for Metvan delivery. Results exhibited that the ideal formulation was obtained by using myristyl myristate as the lipid matrix and Pluronic F128 as the stabilizing agent with a mean nanoparticle size of 230.8 ± 3.1 nm and a mean surface charge of −7.9 ± 0.8 mV. The formulation showed an encapsulation efficiency of approximately 80% with a sustained drug release for more than 60 h. The kinetic release mechanism of Metvan from the nanoparticles fitted the Korsmeyer–Peppas model, indicating the Fickian diffusion of Metvan from the nanoparticles. On the other hand, the results showed that the nanoparticle-Metvan system is more effective to decrease cell viability on human osteosarcoma cells (MG-63) compared to the free drug, suggesting a possible different cell internalization mechanism and intracellular effect.